loading page

Tilapia lake virus (TiLV): Genomic epidemiology and its early origin
  • +3
  • Yuttapong Thawornwattana,
  • Ha Dong,
  • Kornsunee Phiwsaiya,
  • Pakkakul Sangsuriya,
  • Saengchan Senapin,
  • Pakorn Aiewsakun
Yuttapong Thawornwattana
Mahidol University Faculty of Science

Corresponding Author:[email protected]

Author Profile
Ha Dong
Suan Sunandha Rajabhat University
Author Profile
Kornsunee Phiwsaiya
Mahidol University Faculty of Science
Author Profile
Pakkakul Sangsuriya
Author Profile
Saengchan Senapin
Mahidol University Faculty of Science
Author Profile
Pakorn Aiewsakun
Mahidol University Faculty of Science
Author Profile


Tilapia lake virus (TiLV) is an emerging virus that is rapidly spreading across the world. Over the past 6 years (2014–2020), TiLV outbreaks had been reported in at least 16 countries, spanning three continents, including Asia, Africa, and America. Despite its enormous economic impact, its origin, evolution, and epidemiology are still largely poorly characterised. Here, we report eight TiLV whole genome sequences from Thailand sampled between 2014–2019. Together with publicly available sequences from various regions of the world, we estimated the origin of TiLV to be between 2003–2009, 5–10 years before the first report of the virus in Israel in 2014. Our analyses consistently showed that TiLV started to spread in 2000s, and reached its peak in 2014–2016, matching well with the timing of its first report. From 2016 onwards, the TiLV population declined steadily. This could be a result of herd immunity building up in the fish population, and / or a reflection of a better awareness of the virus coupled with a better and more cautious protocol of Tilapia importation. Despite the fact that we included all publicly available sequences, our analyses revealed long unsampled histories of TiLVs in many countries, especially towards its basal diversification. This result highlights the lack and the need for systematic surveillance of TiLV in fish.
30 Apr 2020Submitted to Transboundary and Emerging Diseases
03 May 2020Submission Checks Completed
03 May 2020Assigned to Editor
04 May 2020Reviewer(s) Assigned
27 May 2020Review(s) Completed, Editorial Evaluation Pending
06 Jun 2020Editorial Decision: Revise Major
06 Jun 20201st Revision Received
08 Jun 2020Submission Checks Completed
08 Jun 2020Assigned to Editor
09 Jun 2020Reviewer(s) Assigned
10 Jun 2020Review(s) Completed, Editorial Evaluation Pending
13 Jun 2020Editorial Decision: Accept
Mar 2021Published in Transboundary and Emerging Diseases volume 68 issue 2 on pages 435-444. 10.1111/tbed.13693